IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
This study is ongoing, but not recruiting participants.
Sponsor:
Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT02367794
First received: February 13, 2015
Last updated: June 12, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
| Condition | Intervention | Phase |
|---|---|---|
| Squamous Non-Small Cell Lung Cancer | Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody Drug: Carboplatin Drug: Nab-Paclitaxel Drug: Paclitaxel | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment |
| Official Title: | A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
lung cancer
MedlinePlus related topics:
Lung Cancer
U.S. FDA Resources
Further study details as provided by Hoffmann-La Roche:
Primary Outcome Measures:
- Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Tumor Gene Expression (tGE) Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 30 months after first participant enrolled ]
- PFS as Determined by the Investigator Using RECIST v1.1 in the Intent-to-Treat (ITT) Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 30 months after first participant enrolled ]
- Overall Survival (OS) in the ITT Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
Secondary Outcome Measures:
- OS in the tGE Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 30 months after first participant enrolled ]
- PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 30 months after first participant enrolled ]
- OS in the TC2/3 or IC2/3 Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- OS in the TC1/2/3 or IC1/2/3 Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the tGE Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- Duration of Response as Determined by the Investigator Using RECIST v1.1 in the tGE Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- Percentage of Participants Alive at 1 and 2 Years in the tGE Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: 1 and 2 years ]
- Percentage of Participants Alive at 1 and 2 Years in the ITT Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: 1 and 2 years ]
- Time to Deterioration(TTD) in Patient-reported Lung Cancer Symptoms Using European Organisation for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core (QLQ-C30) Subscales in the tGE Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- TTD in Patient-reported Lung Cancer Symptoms Using EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Subscales in the tGE Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after the first participant enrolled ]
- TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Up to approximately 39 months after the first participant enrolled ]
- Change from Baseline in Patient-reported Lung Cancer Symptoms Score using the Symptoms in Lung Cancer (SILC) Scale Symptom Severity Score in the tGE Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Baseline up to approximately 39 months after first participant enrolled ]
- Change from Baseline in Patient-reported Lung Cancer Symptoms Score using the SILC Scale Symptom Severity Score in the ITT Population (Arm A vs Arm C, Arm B vs Arm C) [ Time Frame: Baseline up to approximately 39 months after first participant enrolled ]
- PFS as Determined by the Investigator Using RECIST v1.1 in the TC2/3 or IC2/3 Population (Arm A vs Arm B) [ Time Frame: Up to approximately 30 months after first participant enrolled ]
- PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population (Arm A vs Arm B) [ Time Frame: Up to approximately 30 months after first participant enrolled ]
- OS in the TC2/3 or IC2/3 Population (Arm A vs Arm B) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- OS in the TC1/2/3 or IC1/2/3 Population (Arm A vs Arm B) [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- Percentage of Participants With Adverse Events [ Time Frame: Up to approximately 39 months after first participant enrolled ]
- Percentage of Participants with Anti-therapeutic Antibody (ATA) Response to Atezolizumab [ Time Frame: Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days) ]The predose samples will be collected on the same day of treatment administration.
- Maximum Observed Serum Atezolizumab Concentration (Cmax) [ Time Frame: Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle up to 39 months; 30 minutes postdose on Day 1 of Cycles 1 and 3; at treatment discontinuation (up to 39 months), and at 120 days after last dose of atezolizumab (up to 39 months, each cycle is 21 days) ]The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.
- Minimum Observed Serum Atezolizumab Concentration (Cmin) [ Time Frame: Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 39 months), at treatment discontinuation (up to 39 months), and at 120 days after the last dose of atezolizumab (up to approximately 39 months, each cycle is 21 days) ]The predose samples will be collected on the same day of treatment administration.
- Plasma Concentrations for Paclitaxel [ Time Frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) ]
- Plasma Concentrations for Nab-Paclitaxel [ Time Frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) ]
- Plasma Concentrations for Carboplatin [ Time Frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) ]
| Estimated Enrollment: | 1025 |
| Actual Study Start Date: | June 11, 2015 |
| Estimated Study Completion Date: | February 15, 2023 |
| Estimated Primary Completion Date: | January 1, 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm A: Atezolizumab + Paclitaxel + Carboplatin
The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
|
Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
Other Name: Tecentriq
Drug: Carboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
Drug: Paclitaxel
Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.
|
|
Experimental: Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
|
Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
Other Name: Tecentriq
Drug: Carboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
Drug: Nab-Paclitaxel
Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
|
|
Active Comparator: Arm C: Nab-Paclitaxel + Carboplatin
The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
|
Drug: Carboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
Drug: Nab-Paclitaxel
Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC
- Previously obtained archival tumor tissue or tissue obtained from biopsy at screening
- Measurable disease as defined by RECIST v1.1
- Adequate hematologic and end organ function
Exclusion Criteria:
- Active or untreated central nervous system (CNS) metastasis
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Pregnant or lactating women
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Positive test for Human Immunodeficiency Virus (HIV)
- Active hepatitis B or hepatitis C
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
- Severe infection within 4 weeks prior to randomization
- Significant history of cardiovascular disease
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02367794
Hide Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT02367794
Hide Study Locations
Locations
| United States, Arizona | |
| Ironwood Cancer & Research Centers | |
| Chandler, Arizona, United States, 85224 | |
| Premiere Oncology | |
| Scottsdale, Arizona, United States, 85258 | |
| United States, Arkansas | |
| Uni of Arkansas For Medical Sciences | |
| Little Rock, Arkansas, United States, 72205 | |
| Highlands Oncology Group | |
| Rogers, Arkansas, United States, 72758 | |
| United States, California | |
| Kaiser Permanente Oakland Medical Center | |
| Oakland, California, United States, 94611 | |
| Kaiser Permanente Medical Center - Roseville | |
| Roseville, California, United States, 95661 | |
| Kaiser Permanente - Sacramento Medical Center and Medical Offices | |
| Sacramento, California, United States, 95825 | |
| Southern CA Permanente Med Grp | |
| San Diego, California, United States, 92120 | |
| Kaiser Permanente - San Francisco Medical Center | |
| San Francisco, California, United States, 94115 | |
| Kaiser Permanente - San Jose Medical Center | |
| San Jose, California, United States, 95119 | |
| Kaiser Permanente - San Leandro Medical Center | |
| San Leandro, California, United States, 94577 | |
| Kaiser Permanente - Santa Clara | |
| Santa Clara, California, United States, 95051 | |
| Kaiser Permanente - South San Francisco | |
| South San Francisco, California, United States, 94080 | |
| Kaiser Permanente; Oncology Clinical Trials | |
| Vallejo, California, United States, 94589 | |
| Kaiser Permanente - Walnut Creek | |
| Walnut Creek, California, United States, 94596 | |
| United States, Colorado | |
| Rocky Mountain Cancer Center | |
| Denver, Colorado, United States, 80218 | |
| United States, Connecticut | |
| Danbury Hospital | |
| Danbury, Connecticut, United States, 06810 | |
| United States, Florida | |
| Holy Cross Hospital Inc | |
| Fort Lauderdale, Florida, United States, 33308 | |
| SCRI Florida Cancer Specialists South | |
| Fort Myers, Florida, United States, 33916 | |
| University of Miami Medical Center | |
| Miami, Florida, United States, 33136 | |
| Florida Cancer Specialists | |
| Palm Beach Gardens, Florida, United States, 33410 | |
| Hematology Oncology Associates of the Treasure Coast | |
| Port Saint Lucie, Florida, United States, 34952 | |
| Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building) | |
| Saint Petersburg, Florida, United States, 33705 | |
| SCRI Florida Cancer Specialists East | |
| Tallahassee, Florida, United States, 32308 | |
| United States, Georgia | |
| University Cancer & Blood Center, LLC | |
| Athens, Georgia, United States, 30607 | |
| Northwest Georgia Oncology Centers P.C. | |
| Carlton, Georgia, United States, 30117 | |
| Suburban Hematology / Oncology Associates | |
| Lawrenceville, Georgia, United States, 30046 | |
| Central Georgia Cancer Care PC | |
| Macon, Georgia, United States, 31201 | |
| Southeastern Regional Medical Center, Inc. | |
| Newnan, Georgia, United States, 30265 | |
| United States, Hawaii | |
| University of Hawaii | |
| Honolulu, Hawaii, United States, 96813 | |
| United States, Illinois | |
| University of Chicago | |
| Chicago, Illinois, United States, 60637 | |
| Joliet Oncology-Hematology; Associates, Ltd. | |
| Joliet, Illinois, United States, 60435 | |
| Loyola University Med Center | |
| Maywood, Illinois, United States, 60153 | |
| Oncology Specialists, S.C. | |
| Park Ridge, Illinois, United States, 60068 | |
| Quincy Medical Group | |
| Quincy, Illinois, United States, 62301 | |
| Southern Illinois University, Simmons Cancer Institute | |
| Springfield, Illinois, United States, 62794 | |
| United States, Indiana | |
| Fort Wayne Med Oncology & Hematology Inc | |
| Fort Wayne, Indiana, United States, 46845 | |
| United States, Iowa | |
| Hematology-Oncology; Associates of the Quad Cities | |
| Bettendorf, Iowa, United States, 52722 | |
| Siouxland Hematology/Oncology | |
| Sioux City, Iowa, United States, 51101 | |
| United States, Kentucky | |
| ARH Regional Medical Center | |
| Hazard, Kentucky, United States, 41701 | |
| Lahey Clinic Med Ctr | |
| Lexington, Kentucky, United States, 02421 | |
| Norton Cancer Institute | |
| Louisville, Kentucky, United States, 40402 | |
| United States, Louisiana | |
| Ochsner Clinic Foundation | |
| New Orleans, Louisiana, United States, 70121 | |
| United States, Maine | |
| New England Cancer Specialists | |
| Scarborough, Maine, United States, 04074 | |
| United States, Maryland | |
| Walter Reed National Military Medical Center | |
| Bethesda, Maryland, United States, 20814 | |
| United States, Massachusetts | |
| Southcoast Health System; Southcoast Centers For Cancer Care | |
| Fairhaven, Massachusetts, United States, 02719 | |
| United States, Michigan | |
| St. Joseph Mercy Health System | |
| Ann Arbor, Michigan, United States, 48106 | |
| Karmanos Cancer Institute | |
| Detroit, Michigan, United States, 48201 | |
| United States, Minnesota | |
| St. Luke's Regional Cancer Center | |
| Duluth, Minnesota, United States, 55805 | |
| United States, Mississippi | |
| Hematology and Oncology Associates at Bridgepoint | |
| Tupelo, Mississippi, United States, 38801 | |
| United States, Missouri | |
| St. Luke's Cancer Institute | |
| Kansas City, Missouri, United States, 64111 | |
| United States, Montana | |
| Billings Clinic | |
| Billings, Montana, United States, 59102 | |
| United States, Nevada | |
| Va Sierra Nevada Health Care System | |
| Reno, Nevada, United States, 89502 | |
| United States, New Jersey | |
| Regional Cancer Care Associates | |
| Cherry Hill, New Jersey, United States, 08003 | |
| Valley Hospital; Oncology Research | |
| Paramus, New Jersey, United States, 07652 | |
| Regional Cancer Care Associates LLC | |
| Sewell, New Jersey, United States, 08080 | |
| United States, New York | |
| Clinical Research Alliance | |
| Lake Success, New York, United States, 11042 | |
| Monter Cancer Center | |
| Lake Success, New York, United States, 11042 | |
| United States, North Carolina | |
| W.G. Bill Hefner VA Medical Center | |
| Salisbury, North Carolina, United States | |
| United States, Ohio | |
| University of Cincinnati | |
| Cincinnati, Ohio, United States, 45203-0542 | |
| Mark H. Zangmeister Center | |
| Columbus, Ohio, United States, 43219 | |
| Oncology Hematology Care, Inc. | |
| Hamilton, Ohio, United States, 45103 | |
| Mercy St Anne Hospital | |
| Toledo, Ohio, United States, 43623 | |
| United States, Oregon | |
| Bend Memorial Clinic | |
| Bend, Oregon, United States, 97701 | |
| St. Charles Medical Center Bend; Cancer Care Of The Cascades | |
| Bend, Oregon, United States, 97701 | |
| Oregon Health & Science Uni | |
| Portland, Oregon, United States, 97239 | |
| United States, Pennsylvania | |
| St. Luke's Cancer Care Associates | |
| Bethlehem, Pennsylvania, United States, 18015 | |
| Maryland Oncology Hematology (Lanham) - USOR | |
| Gettysburg, Pennsylvania, United States, 17325 | |
| Pinnacle Health | |
| Harrisburg, Pennsylvania, United States, 17110 | |
| Lancaster General Hospital | |
| Lancaster, Pennsylvania, United States, 17607 | |
| Allegheny Cancer Center | |
| Pittsburgh, Pennsylvania, United States, 15212 | |
| Univ of Pittsburgh Medical Ctr | |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| United States, Tennessee | |
| SCRI Tennessee Oncology Chattanooga | |
| Chattanooga, Tennessee, United States, 37404 | |
| Tennessee Cancer Specialists | |
| Knoxville, Tennessee, United States, 37920 | |
| United States, Texas | |
| SCRI The Center For Cancer and Blood Disorders | |
| Denton, Texas, United States, 76210 | |
| Longview Cancer Center | |
| Longview, Texas, United States, 75601 | |
| Cancer Care Network of South Texas - SAT & BC | |
| San Antonio, Texas, United States, 78217 | |
| United States, Virginia | |
| Virginia Cancer Specialists, PC | |
| Fairfax, Virginia, United States, 22031 | |
| Virginia Oncology Associates | |
| Norfolk, Virginia, United States, 23502 | |
| Virginia Cancer Institute | |
| Richmond, Virginia, United States, 23226 | |
| Blue Ridge Cancer Care | |
| Roanoke, Virginia, United States, 24014 | |
| United States, Washington | |
| Providence Regional Cancer Partnership | |
| Everett, Washington, United States, 98201 | |
| Medical Oncology Associates | |
| Spokane, Washington, United States, 99208 | |
| United States, West Virginia | |
| West Virginia University; Mary Babb Randolph Can Ctr | |
| Morgantown, West Virginia, United States, 26506 | |
| Argentina | |
| Instituto Alexander Fleming | |
| Buenos Aires, Argentina, 1426 | |
| Fundacion Sanatorio Guemes | |
| Buenos Aires, Argentina, C1180AAX | |
| Fundacion Investigar | |
| Caba, Argentina, C1025ABI | |
| Sanatorio Allende | |
| Cordoba, Argentina, X5000JHQ | |
| Instituto Medico Rio Cuarto | |
| Córdoba, Argentina | |
| Centro Oncologico Riojano Integral (CORI) | |
| La Rioja, Argentina, F5300COE | |
| Clínica Pergamino | |
| Pergamino, Argentina, 2700 | |
| COIBA | |
| Provincia de Buenos Aires, Argentina, B1884BBF | |
| Hospital Provincial del Centenario | |
| Rosario, Argentina, 2000 | |
| Sanatorio Britanico | |
| Rosario, Argentina, 2000 | |
| Fundacion Koriza | |
| Santa Rosa, Argentina, 6300 | |
| Centro de Investigacion; Clinica - Clinica Viedma S.A. | |
| Viedma, Argentina, R8500ACE | |
| Australia, New South Wales | |
| Chris O'Brien Lifehouse | |
| Camperdown, New South Wales, Australia, 2050 | |
| Concord Repatriation General Hospital | |
| Concord, New South Wales, Australia, 2139 | |
| Prince of Wales Hospital; Oncology | |
| Randwick, New South Wales, Australia, 2031 | |
| Nepean Cancer Care Centre | |
| Sydney, New South Wales, Australia, 2747 | |
| Calvary Mater Newcastle; Medical Oncology | |
| Waratah, New South Wales, Australia, 2298 | |
| Australia, Queensland | |
| Prince Charles Hospital | |
| Chermside, Queensland, Australia, 4032 | |
| Icon Cancer Care South Brisbane | |
| South Brisbane, Queensland, Australia, 4101 | |
| Townsville Hospital | |
| Townsville, Queensland, Australia, 4810 | |
| Princess Alexandra Hospital | |
| Woolloongabba, Queensland, Australia, 4102 | |
| Australia, South Australia | |
| Royal Adelaide Hospital | |
| Adelaide, South Australia, Australia, 5000 | |
| Australia, Tasmania | |
| Launceston General Hospital | |
| Launceston, Tasmania, Australia, 7250 | |
| Australia, Victoria | |
| Frankston Hospital | |
| Frankston, Victoria, Australia, 3199 | |
| Austin Health | |
| Heidelberg, Victoria, Australia, 3084 | |
| Cabrini Hospital Malvern | |
| Malvern, Victoria, Australia, 3144 | |
| The Alfred Hospital | |
| Prahan, Victoria, Australia, 3181 | |
| Sunshine Hospital | |
| St Albans, Victoria, Australia, 3021 | |
| Australia, Western Australia | |
| Sir Charles Gairdner Hospital | |
| Nedlands, Western Australia, Australia, 6009 | |
| Austria | |
| Paracelsus Medizinische Privatuniversität | |
| Salzburg, Austria, 5020 | |
| Klinikum Wels-Grieskirchen | |
| Wels, Austria, 4600 | |
| Belgium | |
| Cliniques Universitaires St-Luc | |
| Bruxelles, Belgium, 1200 | |
| CHU Sart-Tilman | |
| Liège, Belgium, 4000 | |
| Clinique Ste-Elisabeth | |
| Namur, Belgium, 5000 | |
| Werken Glorieux VZW | |
| Ronse, Belgium, 9600 | |
| GasthuisZusters Antwerpen | |
| Wilrijk, Belgium, 2610 | |
| Brazil | |
| Cetus Hospital Dia Oncologia | |
| Belo Horizonte, MG, Brazil, 30150-270 | |
| Cenantron - Centro Avancado de Tratamento Oncologico | |
| Belo Horizonte, MG, Brazil, 30150-320 | |
| Instituto Do Cancer Delondrina; Unidade De Pesquisa Clinica | |
| Londrina, PR, Brazil, 86 015 520 | |
| Liga Norte Riograndense Contra O Câncer | |
| Natal, RN, Brazil, 59040150 | |
| IPCEM; Instituto de Pesquisa de Estudos Multicêntricos | |
| Caxias do Sul, RS, Brazil, 95070-560 | |
| Hospital Bruno Born | |
| Lajeado, RS, Brazil, 95900-000 | |
| Hospital das Clinicas - UFRGS | |
| Porto Alegre, RS, Brazil, 90035-003 | |
| Hospital Mae de Deus | |
| Porto Alegre, RS, Brazil, 90470-340 | |
| Fundação Pio XII Hospital de Câncer de Barretos | |
| Barretos, SP, Brazil, 14784-400 | |
| Instituto Ribeirãopretano de Combate Ao Câncer; Centro Especializado De Oncologia | |
| Ribeirão Preto, SP, Brazil, 14015-130 | |
| Hospital de Base de Sao Jose do Rio Preto | |
| Sao Jose do Rio Preto, SP, Brazil, 15090-000 | |
| Fundacao Antonio Prudente | |
| Sao Paulo, SP, Brazil, 01509-900 | |
| UNIFESP Universidade Federal de Sao Paulo EPM | |
| São Paulo, SP, Brazil, 04020-050 | |
| Bulgaria | |
| Multiprofile Hospital for Active Treatment Central Onco Hospital OOD | |
| Plovdiv, Bulgaria, 4000 | |
| Multiprofile Hospital for Active Treatment Serdika EOOD | |
| Sofia, Bulgaria, 1303 | |
| Military Medical Academy - MHAT - Sofia | |
| Sofia, Bulgaria, 1606 | |
| Specialized Hospital for Active Treatment of Oncology Diseases - Sofia city chemotherapy Department | |
| Sofia, Bulgaria, 1784 | |
| Canada, Ontario | |
| Royal Victoria Regional Health Centre | |
| Barrie, Ontario, Canada, L4M 6M2 | |
| William Osler Health Centre | |
| Etobicoke, Ontario, Canada, M9V 1R8 | |
| Lakeridge Health Center | |
| Oshawa, Ontario, Canada, L1J 2J2 | |
| Canada, Quebec | |
| Cite de La Sante de Laval; Hemato-Oncologie | |
| Laval, Quebec, Canada, H7M 3L9 | |
| Hôpital Maisonneuve - Rosemont | |
| Montreal, Quebec, Canada, H1T 2M4 | |
| Hôpital du Sacré-Coeur de Montreal | |
| Montreal, Quebec, Canada, H4J 1C5 | |
| St-Jerome Medical Research Inc | |
| St. Jerome, Quebec, Canada, J7Z 5T3 | |
| Chile | |
| Clinica Santa Maria | |
| Santiago, Chile, 0 | |
| Health & Care SPA | |
| Santiago, Chile, 7500006 | |
| Hospital Clinico de La Universidad de Chile J.J.A.; Oncologia | |
| Santiago, Chile, 8380456 | |
| Instituto Clínico Oncolo gico del Sur | |
| Temuco, Chile, 4810469 | |
| France | |
| Centre Georges François Leclerc | |
| Dijon, France, 21000 | |
| CHU de Grenoble | |
| Grenoble, France, 38043 | |
| Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd | |
| Le Mans, France, 72000 | |
| Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes | |
| Lyon, France, 69008 | |
| Clinique Clémentville | |
| Montpellier, France, 34070 | |
| Hopital de La Source | |
| Orleans, France, 45067 | |
| Centre Hospitalier Lyon Sud | |
| Pierre Benite, France, 69495 | |
| Hopital de Pontchaillou; Service de Pneumologie | |
| Rennes, France, 35033 | |
| Service de Pneumologie Centre Hospitalier Régional La Réunion Site Felix Guyon | |
| Saint Denis Cedex, France, 97405 | |
| Centre Hospitalier Regional Sud Reunion; Service de Pneumologie | |
| Saint Pierre, France, 97448 | |
| CH de Saint Quentin | |
| Saint Quentin, France, 2100 | |
| Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques | |
| Toulon Cedex 9, France, 83800 | |
| Germany | |
| Hämatologisch-onkologische Praxis Dr. med. - Brudler, - Heinrich, - Bangerter | |
| Augsburg, Germany, 86150 | |
| Charite - Universitätsmedizin Berlin | |
| Berlin, Germany, 10117 | |
| Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie | |
| Bielefeld, Germany, 33611 | |
| Augusta Kranken-Anstalt gGmbH | |
| Bochum, Germany, 44791 | |
| Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden | |
| Dresden, Germany, 01307 | |
| St. Elisabethen Krankenhaus | |
| Frankfurt am Main, Germany, 60487 | |
| Franziskus-Hospital Harderberg | |
| Georgsmarienhutte, Germany, 49124 | |
| Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie | |
| Gerlingen, Germany, 70839 | |
| LungenClinic Großhansdorf | |
| Großhansdorf, Germany, 22927 | |
| Krankenhaus Martha-Maria; Halle-Dolau gGmbH | |
| Halle, Germany, 06120 | |
| Universitätsklinikum Hamburg-Eppendorf | |
| Hamburg, Germany, 20246 | |
| Asklepios Klinik Harburg | |
| Hamburg, Germany, 21075 | |
| Hämato-Onkologie Hamburg | |
| Hamburg, Germany, 21075 | |
| Lungenklinik Hemer | |
| Hemer, Germany, 58675 | |
| Universität Des Saarlandes; Klinik für Innere Medizin V | |
| Homburg, Germany, 66421 | |
| Fachklinik für Lungenerkrankungen | |
| Immenhausen, Germany, 34376 | |
| Kliniken der Stadt Koln gGmbH | |
| Koln, Germany, 51109 | |
| Klinik Loewenstein gGmbH; Onk & Pal | |
| Loewenstein, Germany, 74245 | |
| Johannes Wesling Klinikum Minden | |
| Minden, Germany, 32429 | |
| Universitätsklinikum Münster; Pädiatrische Hämatologie und Onkologie | |
| Munster, Germany, 48149 | |
| Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie | |
| München, Germany, 81925 | |
| Krankenhaus Barmherzige Bruder Regensburg | |
| Regensburg, Germany, 93049 | |
| Klinikum der Universität Regensburg | |
| Regensburg, Germany, 93053 | |
| Stiftung Mathias-Spital Rheine | |
| Rheine, Germany, 48431 | |
| Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie | |
| Villingen-Schwenningen, Germany, 78052 | |
| Israel | |
| Soroka Medical Center | |
| Beer Sheva, Israel, 8410101 | |
| Assaf Harofeh Medical Center | |
| Beer Yaakov, Israel, 70300 | |
| Hadassah University Hospital - Ein Kerem | |
| Jerusalem, Israel, 9112001 | |
| Meir Medical Center; Oncology | |
| Kfar-Saba, Israel, 4428164 | |
| Galilee Medical Center | |
| Nahariya, Israel, 22100 | |
| Rabin Medical Center | |
| Petah Tikva, Israel, 4941492 | |
| Chaim Sheba Medical Center; Oncology Dept | |
| Ramat Gan, Israel, 5262100 | |
| Rambam Health Corporation; Oncology Institute | |
| Rambam, Israel, 3525408 | |
| Kaplan Medical Center | |
| Rehovot, Israel, 76100 | |
| Tel Aviv Sourasky Medical Ctr; Oncology | |
| Tel Aviv, Israel, 6423906 | |
| Italy | |
| Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati | |
| Avellino, Campania, Italy, 83100 | |
| AORN A Cardarelli | |
| Napoli, Campania, Italy, 80131 | |
| Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata | |
| Napoli, Campania, Italy, 80131 | |
| Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale | |
| Napoli, Campania, Italy, 80131 | |
| Azienda Ospedaliera San Camillo Forlanini | |
| Roma, Lazio, Italy, 00151 | |
| ASL 3 Genovese; DSM | |
| Genova, Liguria, Italy, 16147 | |
| Fondazione IRCCS Policlinico San Matteo | |
| Pavia, Lombardia, Italy, 27100 | |
| A.O.U. Maggiore della Carità | |
| Novara, Piemonte, Italy, 28100 | |
| IRCCS Giovanni Paolo II Istituto Oncologico | |
| Bari, Puglia, Italy, 70124 | |
| Policlinico Vittorio Emanuele | |
| Catania, Sicilia, Italy, 95123 | |
| Ospedale Civile - Livorno | |
| Livorno, Toscana, Italy, 57124 | |
| Azienda Ospedaliero Universitaria Pisana | |
| Pisa, Toscana, Italy, 56100 | |
| Ospedale Silvestrini | |
| Perugia, Umbria, Italy, 06122 | |
| Japan | |
| Aichi Cancer Center Hospital; Respiratory Medicine | |
| Aichi, Japan, 464-8681 | |
| Nagoya University Hospital; Respiratory Medicine | |
| Aichi, Japan, 466-8560 | |
| National Cancer Center Hospital East; Thoracic Oncology | |
| Chiba, Japan, 277-8577 | |
| National Hospital Organization Shikoku Cancer Center; Internal Medicine | |
| Ehime, Japan, 791-0280 | |
| National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine | |
| Fukuoka, Japan, 810-8563 | |
| Kyushu University Hospital; Respiratory | |
| Fukuoka, Japan, 812-8582 | |
| Institute of Biomedical Research and Innovation Hospital; Integrated Oncology | |
| Hyogo, Japan, 650-0047 | |
| National Hospital Organization Himeji Medical Center | |
| Hyogo, Japan, 670-8520 | |
| Hyogo Cancer Center; Thoracic Oncology | |
| Hyogo, Japan, 673-8553 | |
| Ibaraki Prefectural Central Hospital; Division of respiratory | |
| Ibaraki, Japan, 309-1793 | |
| Kanagawa Cancer Center;Thoracic Oncology | |
| Kanagawa, Japan, 241-8515 | |
| Kyoto University Hospital, Respiratory Medicine | |
| Kyoto, Japan, 606-8507 | |
| Sendai Kousei Hospital; Pulmonary Medicine | |
| Miyagi, Japan, 980-0873 | |
| Niigata University Medical & Dental Hospital; Respiratory Medicine and Infectious Disease | |
| Niigata, Japan, 951-8520 | |
| Okayama University Hospital; Respiratory and Allergy Medicine | |
| Okayama, Japan, 700-8558 | |
| Osaka International Cancer Institute; Thoracic Oncology | |
| Osaka, Japan, 541-8567 | |
| Osaka City Uni Hospital; Respiratory Medicine | |
| Osaka, Japan, 545-8586 | |
| Kansai Medical university Hospital; Thoracic Oncology | |
| Osaka, Japan, 573-1191 | |
| Osaka Habikino Medical Center | |
| Osaka, Japan, 583-8588 | |
| Saitama Cancer Center; Thoracic Oncology | |
| Saitama, Japan, 362-0806 | |
| National Hospital Organization Kinki-Chuo Chest Medical Center | |
| Sakai-shi, Japan, 591-8555 | |
| Shizuoka Cancer Center; Thoracic Oncology | |
| Shizuoka, Japan, 411-8777 | |
| National Cancer Center Hospital; Thoracic Medical Oncology | |
| Tokyo, Japan, 104-0045 | |
| Tokyo Medical University Hospital; Dept of Surgery | |
| Tokyo, Japan, 160-0023 | |
| Latvia | |
| Riga East Clinical University Hospital Latvian Oncology Centre | |
| Riga, Latvia, LV-1079 | |
| Pauls Stradins Clinical University Hospital | |
| Riga, Latvia, LV1002 | |
| Lithuania | |
| National Cancer Institute | |
| Vilnius, Lithuania, 08660 | |
| Mexico | |
| Centro Universitario Contra El Cancer | |
| Monterrey, Mexico, 64020 | |
| Cancerología | |
| Queretaro, Mexico, 76090 | |
| Netherlands | |
| VU Medisch Centrum; VU University Medical Center | |
| Amsterdam, Netherlands, 1007 MB | |
| Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis | |
| Amsterdam, Netherlands, 1066 CX | |
| Amphia Ziekenhuis; Afdeling Longziekten | |
| Breda, Netherlands, 4818 CK | |
| Ziekenhuis Gelderse Vallei | |
| EDE, Netherlands, 6716 RP | |
| Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose | |
| Eindhoven, Netherlands, 5623 EJ | |
| Spaarne Gasthuis; Spaarne Ziekenhuis | |
| Hoofddorp, Netherlands, 2134 TM | |
| Maastricht University Medical Center | |
| Maastricht, Netherlands, 6229 HX | |
| St. Antonius Ziekenhuis; R&D Long | |
| Nieuwegein, Netherlands, 3435 CM | |
| Peru | |
| Centro Medico Monte Carmelo | |
| Arequipa, Peru, 04001 | |
| Centro Especializado de Enfermedades Neoplásicas | |
| Arequipa, Peru | |
| Instituto Nacional de Enfermedades Neoplasicas | |
| Lima, Peru, 34 | |
| Hospital Nacional Guillermo Almenara Irigoyen ESSALUD | |
| Lima, Peru, Lima 13 | |
| Instituto Regional de Enfermedades Neoplásicas Del Norte | |
| Trujillo, Peru, 12345 | |
| Portugal | |
| Centro Hospitalar E Universitário de Coimbra EPE | |
| Coimbra, Portugal, 3000-602 | |
| IPO de Lisboa; Servico de Pneumologia | |
| Lisboa, Portugal, 1099-023 | |
| Hospital Pulido Valente; Servico de Pneumologia | |
| Lisboa, Portugal, 1796-001 | |
| Centro Hospitalar do Porto - Hospital de Santo António | |
| Porto, Portugal, 4099-001 | |
| Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe | |
| Porto, Portugal, 4200-072 | |
| Hospital de Sao Joao; Servico de Pneumologia | |
| Porto, Portugal, 4200 | |
| Russian Federation | |
| Moscow City Oncology Hospital #62 | |
| Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation, 143423 | |
| Russian Oncology Research Center n.a. N.N. Blokhin | |
| Moscow, Russian Federation, 115478 | |
| Clinical Oncology Dispensary | |
| Omsk, Russian Federation, 644013 | |
| City Clinical Oncology Dispensary | |
| Saint-Petersburg, Russian Federation, 197022 | |
| Russian Medical Military Academy n.a. S.M. Kirov; Thoracic Surgery Department | |
| St. Petersburg, Russian Federation, 194044 | |
| Volgograd Regional Clinical Oncology Dispensary | |
| Volgograd, Russian Federation, 400138 | |
| Singapore | |
| National University Hospital | |
| Singapore, Singapore, 119074 | |
| National Cancer Centre | |
| Singapore, Singapore, 169610 | |
| Slovakia | |
| Univerzitna nemocnica Bratislava | |
| Bratislava, Slovakia, 813 69 | |
| Narodny onkologicky ustav | |
| Bratislava, Slovakia, 833 01 | |
| POKO Poprad s.r.o. | |
| Poprad, Slovakia, 058 01 | |
| Spain | |
| Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia | |
| L'Hospitalet de Llobregat, Barcelona, Spain, 08007 | |
| Corporacio Sanitaria Parc Tauli; Servicio de Oncologia | |
| Sabadell, Barcelona, Spain, 08208 | |
| Hospital Universitario Marques de Valdecilla; Servicio de Oncologia | |
| Santander, Cantabria, Spain, 39008 | |
| Hospital Universitario Son Espases | |
| Palma De Mallorca, Islas Baleares, Spain, 07014 | |
| Complejo Hospitalario Universitario A Coruña | |
| A Coruña, La Coruña, Spain, 15006 | |
| Complejo Hospitalario Universitario Insular-Materno Infantil | |
| Las Palmas de Gran Canaria, Las Palmas, Spain, 35016 | |
| Hospital Nuestra Senora de Valme | |
| Seville, Sevilla, Spain, 41014 | |
| Hospital Universitario de Canarias | |
| S. Cristobal de la Laguna, Tenerife, Spain, 38320 | |
| Hospital del Mar | |
| Barcelona, Spain, 08003 | |
| Hospital Univ Vall d'Hebron; Servicio de Oncologia | |
| Barcelona, Spain, 08035 | |
| Hospital Clinic de Barcelona | |
| Barcelona, Spain, 08036 | |
| Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia | |
| Barcelona, Spain, 08041 | |
| Hospital Universitario Reina Sofia | |
| Cordoba, Spain | |
| Hospital Lucus Augusti; Servicio de Oncologia | |
| Lugo, Spain, 27003 | |
| Hospital General Universitario Gregorio Marañon; Servicio de Oncologia | |
| Madrid, Spain, 28007 | |
| Hospital Universitario La Paz | |
| Madrid, Spain, 280146 | |
| Hospital Ramon y Cajal; Servicio de Oncologia | |
| Madrid, Spain, 28034 | |
| Fundación Jimenez Díaz | |
| Madrid, Spain, 28040 | |
| Hospital Clinico San Carlos; Servicio de Oncologia | |
| Madrid, Spain, 28040 | |
| Hospital Universitario 12 de Octubre | |
| Madrid, Spain, 28041 | |
| HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia | |
| Madrid, Spain, 28050 | |
| Hospital Clinico Universitario de Valencia | |
| Valencia, Spain, 46010 | |
| Hospital General Universitario de Valencia | |
| Valencia, Spain, 46014 | |
| Hospital Universitario Miguel Servet | |
| Zaragoza, Spain, 50009 | |
| Switzerland | |
| Universitatsspital Bern; Klinik und Poliklinik fur Medizinische Onkologie | |
| Bern, Switzerland, 3010 | |
| Taiwan | |
| Changhua Christian Hospital; Hematology-Oncology | |
| Changhua, Taiwan, 500 | |
| Kaohsiung Medical University Hospital; Department of Urology | |
| Kaohsiung City, Taiwan, 807 | |
| Chi Mei Medical Center Liou Ying Campus | |
| Liuying Township, Taiwan, 736 | |
| Chang Gung Memorial Hospital Chiayi | |
| Putzu, Taiwan, 613 | |
| China Medical University Hospital | |
| Taichung, Taiwan, 40447 | |
| Taichung Veterans General Hospital | |
| Taichung, Taiwan, 407 | |
| Taipei Veterans General Hospital | |
| Taipei, Taiwan, 00112 | |
| National Taiwan Uni Hospital | |
| Taipei, Taiwan, 100 | |
| Mackay Memorial Hospital | |
| Taipei, Taiwan, 104 | |
| Cheng Hsin General Hospital | |
| Taipei, Taiwan, 112 | |
| Tri-Service General Hospital | |
| Taipei, Taiwan, 11490 | |
| Chang Gung Medical Foundation Linkou Branch | |
| Taoyuan City, Taiwan, 333 | |
| Ukraine | |
| Municipal Noncommercial Institution Regional Center of Oncology; Chemotherapy Department #1 | |
| Kharkiv, Kharkiv Governorate, Ukraine, 61070 | |
| Vinnytsya Regional Clinical Oncology Dispensary | |
| Vinnytsya, Podolia Governorate, Ukraine, 21029 | |
| Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1 | |
| Chernivtsi, Ukraine, 58013 | |
| Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU; Chair of Oncology and Medical Radiology | |
| Dnipropetrovsk, Ukraine, 49102 | |
| SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine | |
| Kharkiv, Ukraine, 61024 | |
| MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department | |
| Kryvyi Rih, Ukraine, 50048 | |
| Treatment and Prevention Institution Volyn Regional Oncology Dispensary | |
| Lutsk, Ukraine, 43018 | |
| Lviv State Oncology Regional Treatment and Diagnostic Centre | |
| Lviv, Ukraine, 79031 | |
| Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department | |
| Poltava, Ukraine, 36011 | |
| Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary | |
| Sumy, Ukraine, 40005 | |
| Transcarpathian Regional Clinical Oncology Dispensary; Chemotherapy Department | |
| Uzhhorod, Ukraine, 88014 | |
| Uzhgorod Central City Clinical Hospital | |
| Uzhhorod, Ukraine | |
| MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology | |
| Zaporizhzhya, Ukraine, 69040 | |
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
More Information
| Responsible Party: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT02367794 History of Changes |
| Other Study ID Numbers: |
GO29437 2014-003208-59 ( EudraCT Number ) |
| Study First Received: | February 13, 2015 |
| Last Updated: | June 12, 2017 |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Paclitaxel Albumin-Bound Paclitaxel |
Carboplatin Antibodies Immunoglobulins Antibodies, Monoclonal Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on July 21, 2017